Alan B. Sandler - 07 Nov 2022 Form 4 Insider Report for Mirati Therapeutics, Inc.

Role: Chief Medical Officer
Signature: /s/ Reena R. Desai, as Attorney-In-Fact
Issuer symbol: N/A
Transactions as of: 07 Nov 2022
Net transactions value: $0
Form type: 4
Filing time: 08 Nov 2022, 17:00:19 UTC
Previous filing: 27 Jun 2022
Next filing: 10 Aug 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MRTX	Common Stock	Award	$0	+40,000		$0.000000	40,000	07 Nov 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MRTX	Stock Option (Right to buy)	Award	$0	+65,000		$0.000000	65,000	07 Nov 2022	Common Stock	65,000	$0.000000	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This represents a Restricted Stock Unit grant with a vesting period of 4 years that vests 25% annually from grant date and subject to the reporting persons continuously service to the issuer.
F2	25% of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested.